Compare Inovio Pharmaceuticals Inc (INO) vs Utilities Select Sector SPDR Fund (XLU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Utilities Select Sector SPDR Fund — how do they compare? Inovio Pharmaceuticals Inc trades at $1.12 (market cap $112.19M), while Utilities Select Sector SPDR Fund trades at $41.42 (market cap $23.60B). The key difference: Utilities Select Sector SPDR Fund is far larger — about 210.4× Inovio Pharmaceuticals Inc's market cap, and Utilities Select Sector SPDR Fund is more actively traded (28,758,237 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Utilities Select Sector SPDR Fund for 80 Days on average.
| INO | XLU | |
|---|---|---|
Market Cap | $112.19M | $23.60B |
Volume | 3,201,278 | 28,758,237 |
Sector | Health | — |
52-Week High | $2.65 | $47.73 |
52-Week Low | $0.66 | $39.25 |
Typical Hold Time | 43 Days | 80 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals (INO) trades at $1.09, down 5.63% today, reflecting ongoing financial challenges with minimal revenue of $65,340 in 2025 and substantial losses. The company shows consistent negative cash flow from operations but has beaten EPS estimates in recent quarters. Technical indicators are bearish, with moving averages and oscillators signaling selling pressure. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, its lead candidate for recurrent respiratory papillomatosis.
The investment case hinges on FDA approval of INO-3107, with analyst consensus target at $2.75 offering significant upside. However, high burn rate, negative margins, and dependence on financing pose substantial risks. Positive regulatory outcome could drive revaluation, but failure may exacerbate financial strain. Wall Street maintains cautious optimism with 59% buy ratings.
XLU trades at $41.35, up 0.49% with a mixed technical signal showing bullish moving averages but neutral oscillators. The ETF recently hit 52-week lows amid utility sector pressure from rising interest rates. Support levels cluster around $40-41 with resistance at $42. Recent news highlights oversold conditions and defensive positioning opportunities.
The outlook remains cautious with interest rate sensitivity being the primary risk. Defensive characteristics may appeal during market volatility, but sector headwinds from AI power demand shifts and regulatory challenges require monitoring. Current technical positioning suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Utilities Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: electric utilities; water utilities; multi-utilities; independent power and renewable electricity producers; and gas utilities. The fund is non-diversified.
Read more on XLU →
